**Core Concept**
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. It acts by selectively blocking the action of angiotensin II at its receptor site, leading to vasodilation and a decrease in blood pressure.

**Why the Correct Answer is Right**
Telmisartan competes with angiotensin II for binding to the AT1 receptor, preventing vasoconstriction and aldosterone-mediated sodium retention. This results in decreased peripheral resistance and a subsequent reduction in blood pressure. The blockade of AT1 receptors also leads to a decrease in the release of aldosterone, which in turn reduces sodium reabsorption and water retention in the kidneys.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately describe the mechanism of action of telmisartan. While beta-blockers do lower blood pressure, they act through a different mechanism involving the blockade of beta-adrenergic receptors.

**Option B:** This option is incorrect because it describes the mechanism of action of calcium channel blockers, which act by inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation.

**Option C:** This option is incorrect because it describes the mechanism of action of ACE inhibitors, which act by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing the levels of angiotensin II available to bind to its receptor.

**Option D:** This option is incorrect because it is too vague and does not accurately describe the specific mechanism of action of telmisartan.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that ARBs like telmisartan can cause hyperkalemia as a side effect, particularly in patients with renal impairment or those taking potassium-sparing diuretics. Monitoring of potassium levels is crucial in these patients.

**Correct Answer:** C. Inhibiting the conversion of angiotensin I to angiotensin II is incorrect - it is actually the conversion of angiotensin I to angiotensin II that is inhibited by ACE inhibitors.